The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | The role of elotuzumab in the myeloma treatment algorithm
Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, New York, NY, comments on the role of elotuzumab in the myeloma treatment algorithm. He mentions the lack of evidence for elotuzumab in the newly diagnosed setting, but highlights its efficacy in the relapsed setting, particularly in combination approaches. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
So, elotuzumab has been evaluated as monotherapy and as combination therapy for relapsed myeloma. It has actually also been evaluated in untreated myeloma in combination with RVd. Some of the trials have not been actually able to establish superiority of addition of elotuzumab in the backbone of RVd for untreated myeloma. Having said that, there is some evidence of efficacy being seen in patients with relapsed and refractory myeloma, especially in patients who receive elotuzumab in combination with lenalidomide or elotuzumab in combination with pomalidomide or dexamethasone...
So, elotuzumab has been evaluated as monotherapy and as combination therapy for relapsed myeloma. It has actually also been evaluated in untreated myeloma in combination with RVd. Some of the trials have not been actually able to establish superiority of addition of elotuzumab in the backbone of RVd for untreated myeloma. Having said that, there is some evidence of efficacy being seen in patients with relapsed and refractory myeloma, especially in patients who receive elotuzumab in combination with lenalidomide or elotuzumab in combination with pomalidomide or dexamethasone. So I believe in the modern treatment landscape, when many of our patients are actually receiving CD38-based monoclonal antibodies like daratumumab and isatuximab for frontline therapy as well as maintenance when they progress, there is a potential role for use of elotuzumab in combination with therapies like elotuzumab, pomalidomide, dexamethasone, or elotuzumab, bortezomib, dexamethasone-based combination for these patients, as these patients are not only LEN, but also daratumumab refractory. I also think that upon relapse on CD38-based antibody, carfilzomib may not be an option for every single patient, so combination of elotuzumab becomes important for this particular patient population.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
